61 related articles for article (PubMed ID: 2049323)
1. Modelling recurrence and second cancer risks induced by proton therapy.
Manem VSK; Dhawan A
Math Med Biol; 2018 Sep; 35(3):347-361. PubMed ID: 29106564
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and Radiation Induced Pulmonary Dysfunction in Hodgkin Lymphoma Patients.
Guner SI; Yanmaz MT; Selvi A; Usul C
Indian J Hematol Blood Transfus; 2016 Dec; 32(4):431-436. PubMed ID: 27812252
[TBL] [Abstract][Full Text] [Related]
3. [IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].
Pilz K; Jentsch C; Krause M
Strahlenther Onkol; 2016 Jun; 192(6):428-30. PubMed ID: 27194138
[No Abstract] [Full Text] [Related]
4. Pregnancy-associated cardiomyopathy in survivors of childhood cancer.
Hines MR; Mulrooney DA; Hudson MM; Ness KK; Green DM; Howard SC; Krasin M; Metzger ML
J Cancer Surviv; 2016 Feb; 10(1):113-21. PubMed ID: 26044903
[TBL] [Abstract][Full Text] [Related]
5. Secondary cancer in a survivor of Hodgkin's lymphoma: A case report and review of the literature.
Lisik-Habib M; Czernek U; Dębska-Szmich S; Krakowska M; Kubicka-Wołkowska J; Potemski P
Oncol Lett; 2015 Feb; 9(2):964-966. PubMed ID: 25621073
[TBL] [Abstract][Full Text] [Related]
6. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era.
LeMieux MH; Solanki AA; Mahmood U; Chmura SJ; Koshy M
Cancer Med; 2015 Apr; 4(4):513-8. PubMed ID: 25620577
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of dose escalation on TCP, recurrence and second cancer risks: a mathematical study.
Manem VS; Dhawan A; Kohandel M; Sivaloganathan S
Br J Radiol; 2014 Nov; 87(1043):20140377. PubMed ID: 25210783
[TBL] [Abstract][Full Text] [Related]
8. Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma.
Yeoh KW; Mikhaeel NG
Adv Hematol; 2011; 2011():258797. PubMed ID: 20981157
[TBL] [Abstract][Full Text] [Related]
9. Nodular lymphocyte-predominant Hodgkin's lymphoma.
Nogovà L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
[TBL] [Abstract][Full Text] [Related]
11. Late effects of treatment for early-stage Hodgkin's disease.
Brierley JD; Rathmell AJ; Gospodarowicz MK; Sutcliffe SB; Munro A; Tsang R; Pintilie M
Br J Cancer; 1998 Apr; 77(8):1300-10. PubMed ID: 9579837
[TBL] [Abstract][Full Text] [Related]
12. Radiation induced coronary heart disease.
Sebag-Montefiore D; Hope-Stone H
Br Heart J; 1993 Jun; 69(6):481-2. PubMed ID: 8343311
[No Abstract] [Full Text] [Related]
13. Hodgkin's lymphoma. II: Treatment and delayed morbidity.
Carde P
BMJ; 1992 Jul; 305(6846):173-6. PubMed ID: 1489407
[No Abstract] [Full Text] [Related]
14. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group.
Cosset JM; Henry-Amar M; Meerwaldt JH
Ann Oncol; 1991 Feb; 2 Suppl 2():77-82. PubMed ID: 2049323
[No Abstract] [Full Text] [Related]
15. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease.
Aviles A; Delgado S
Clin Lab Haematol; 1998 Apr; 20(2):95-9. PubMed ID: 9681219
[TBL] [Abstract][Full Text] [Related]
16. Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience.
Koletsky AJ; Bertino JR; Farber LR; Prosnitz LR; Kapp DS; Fischer D; Portlock CS
J Clin Oncol; 1986 Mar; 4(3):311-7. PubMed ID: 3950674
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
18. Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease.
Valagussa P; Santoro A; Bonadonna G
Ann Oncol; 1992 Sep; 3 Suppl 4():111-5. PubMed ID: 1450071
[TBL] [Abstract][Full Text] [Related]
19. [Incidence and significance of therapy-associated late toxicity in Hodgkin's disease].
Streit M; Thiel E; Kreuser ED
Dtsch Med Wochenschr; 1995 Aug; 120(31-32):1093-9. PubMed ID: 7641593
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
